According to GlobalData’s medical device pipeline database, five PET Imaging Agents devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
All five devices of this category are in active stage of development. All devices are in the early stages of development.
PET imaging agents are compounds that contain a small amount of material that emits radiation, called radiotracers. They are introduced into the body typically via injection, accumulate in particular areas, and can then be detected by PET molecular imaging cameras to help provide a detailed image of what is happening inside that area of the body. PET Imaging Agents includes Copper-Based PET Imaging Agents, Fluorine-Based PET Imaging Agents, Gallium-68-Based PET Imaging Agents, and Rubidium-Based PET Imaging Agents.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed PET Imaging Agents pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of PET Imaging Agents devices. Overall, most of these PET Imaging Agents pipeline devices are being developed by private entities.
Key players involved in the active development of PET Imaging Agents include Centre for Probe Development and Commercialization, Stanford University and Stanford University.
For a complete picture of the developmental pipeline for PET Imaging Agents devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
